Plant Name: Dendrobium candidum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| TSHR; | |
| MGAM; ACHE; GAA; | |
| TDP1; BLM; CDA; RECQL; CTDSP1; PKM; ADK; GLO1; HSD17B1; CBR1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALOX12; NOX4; USP2; TNKS; PARP1; TNKS2; POLB; CD38; AOX1; | |
| CFTR; | |
| CSNK2A1; DAPK1; SYK; FLT3; ABL1; GSK3B; MAPK1; EGFR; CDK6; | |
| CA12; CA3; CA14; CA7; CA5A; CA1; CA9; CA4; CA6; CA2; | |
| AR; | |
| ESRRB; ESRRA; | |
| PPARA; PPARD; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS2; TYR; XDH; | |
| ELANE; | |
| MMP12; MMP2; MMP9; | |
| TLR2; | |
| AHR; STAT6; HIF1A; TP53; | |
| SLC28A2; SLC28A1; SLC28A3; SLCO1B3; SLCO1B1; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; HTT; RAB9A; NPC1; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.700E-13 | 1.763E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.322E-13 | 3.765E-10 | AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CDA, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP12, MMP2, MMP9, PARP1, PPARA, PPARD, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.298E-12 | 1.668E-09 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, TBXAS1, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.256E-11 | 7.013E-09 | ABL1, ADORA2A, CA2, CA7, CFTR, EGFR, HIF1A, HTT, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.471E-11 | 2.213E-08 | ABL1, ADORA1, ADORA2A, CA2, CA7, CD38, CDK6, CFTR, EGFR, HIF1A, HTT, MAPK1, NPC1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.744E-11 | 3.442E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.330E-10 | 1.635E-07 | ABCG2, ACHE, ADORA2A, AOX1, APP, BLM, CD38, CDA, CSNK2A1, DAPK1, EGFR, ESR1, ESR2, FLT3, HTT, MAPK1, MAPT, MMP9, PARP1, PKM, PTGS2, RAB9A, SMN1, SMN2, STAT6, TP53, TTR, TYR, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.729E-10 | 2.604E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.320E-09 | 3.686E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.048E-08 | 2.259E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.165E-08 | 2.462E-06 | ABCC1, ALOX12, ALOX15, ALOX5, SYK, TLR2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.599E-08 | 3.165E-06 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.735E-08 | 1.099E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 8.695E-08 | 1.352E-05 | ADORA2A, APP, EGFR, MAPT |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.104E-07 | 1.659E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.375E-07 | 4.593E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.529E-07 | 6.960E-05 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.717E-07 | 7.155E-05 | ABCC1, ADORA1, CA2, CA4, CA9, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.221E-06 | 1.414E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | GO:0051179; localization | GO:0006869; lipid transport | 1.370E-06 | 1.553E-04 | ABCC1, ABCG2, CFTR, FABP3, HTT, NPC1, PPARA, PPARD, SLCO1B1, SLCO1B3 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 2.861E-06 | 2.966E-04 | AKR1B1, EGFR, ELANE, MMP2, MMP9, PTGS2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 3.714E-06 | 3.784E-04 | ADORA1, ADORA2A, ADORA3, APP, AR, CDK6, CYP1B1, FABP3, LMNA, NOX4, PPARD, PTGS2, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 3.817E-06 | 3.866E-04 | AHR, AR, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 4.468E-06 | 4.422E-04 | CYP1A1, EGFR, PPARD, PTGS2, TP53, TYR |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 4.783E-06 | 4.609E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.409E-06 | 5.143E-04 | AR, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 7.681E-06 | 6.940E-04 | EGFR, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.186E-06 | 7.305E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 1.060E-05 | 9.086E-04 | ABCC1, ABCG2, FABP3, HTT, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.139E-05 | 9.541E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.139E-05 | 9.541E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.256E-05 | 1.032E-03 | APP, EGFR, MAPK1, PARP1, PTGS2, TLR2 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.621E-05 | 1.270E-03 | CA2, CA7, CFTR |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.641E-05 | 1.281E-03 | ABL1, ADORA1, ADORA2A, APP, CD38, MAPK1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.813E-05 | 1.400E-03 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.988E-05 | 1.498E-03 | CYP1A2, EGFR, MAPK1, MMP9 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.988E-05 | 1.498E-03 | ABL1, ALOX12, APP, EGFR, ELANE, HIF1A, MAPK1, MMP9, NOX4, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.101E-05 | 1.567E-03 | AR, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.188E-05 | 1.621E-03 | AKR1B1, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.221E-05 | 1.628E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 2.221E-05 | 1.628E-03 | CBR1, PTGS2, TBXAS1 |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 2.221E-05 | 1.628E-03 | GSK3B, HTT, MAPT |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.263E-05 | 1.648E-03 | AHR, CSNK2A1, HIF1A, MAPT |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 2.464E-05 | 1.777E-03 | EGFR, MAPK1, MAPT, PPARA, STAT6, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 2.707E-05 | 1.865E-03 | AOX1, XDH |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 2.707E-05 | 1.865E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.707E-05 | 1.865E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 2.707E-05 | 1.865E-03 | CDA, MAPK1 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.707E-05 | 1.865E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.707E-05 | 1.865E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.707E-05 | 1.865E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 2.707E-05 | 1.865E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.950E-05 | 1.995E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.950E-05 | 1.995E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.125E-05 | 2.094E-03 | ADORA1, ADORA2A, CYP19A1, ELANE, PPARA, PPARD |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 3.270E-05 | 2.158E-03 | BLM, GSK3B, HIF1A, HTT, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 3.281E-05 | 2.159E-03 | AHR, AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 3.385E-05 | 2.200E-03 | ABL1, APP, CDK6, EGFR, GSK3B, HIF1A, MAPK1, MAPT, PARP1, PTGS2, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 3.820E-05 | 2.418E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.820E-05 | 2.418E-03 | ADORA2A, CA2, CA7 |
| MF | GO:0005488; binding | GO:0043168; anion binding | 4.314E-05 | 2.676E-03 | ABCC1, ABCG2, ABL1, ADK, ALOX15, AOX1, APP, BLM, CDK6, CFTR, CSNK2A1, DAPK1, EGFR, ELANE, FABP2, FABP3, FABP4, FABP5, FLT3, GSK3B, HSD17B1, MAPK1, NOX4, PKM, PPARD, RAB9A, RECQL, SYK, TP53, XDH |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 4.385E-05 | 2.713E-03 | ALOX5, CDA, ELANE, FABP5, GAA, MAPK1, MGAM, MMP9, PKM, TLR2, TTR |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 4.534E-05 | 2.797E-03 | MMP2, MMP9, PPARD, PTGS2 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.547E-05 | 2.797E-03 | ABL1, ADK, AHR, AKR1B1, ALOX12, ALOX15, ALOX5, AOX1, APP, AR, BLM, CA1, CA2, CA3, CA7, CBR1, CDA, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, HTT, LMNA, MAPK1, MAPT, PKM, RAB9A, SMN1, SMN2, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 4.775E-05 | 2.912E-03 | ADORA1, ADORA2A, CD38, EGFR, PPARD, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 4.775E-05 | 2.912E-03 | CD38, CYP1A2, EGFR, ESR1, ESRRA, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 4.840E-05 | 2.944E-03 | AKR1B1, CD38, EGFR, FABP3, HSD17B2, MMP2, PTGS2, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 5.187E-05 | 3.120E-03 | ALOX15, EGFR, PPARA, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 5.187E-05 | 3.120E-03 | ABL1, GSK3B, MAPT, PARP1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 5.703E-05 | 3.402E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 5.956E-05 | 3.534E-03 | ABCG2, CFTR, NPC1, SLCO1B1, SLCO1B3, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 6.032E-05 | 3.559E-03 | CA2, EGFR, SYK |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 7.395E-05 | 4.194E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 7.652E-05 | 4.306E-03 | ABL1, CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, SYK |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 7.870E-05 | 4.330E-03 | ABL1, ADORA2A, CYP1B1, DAPK1, GSK3B, HTT, MAPT, MMP9, NOX4, PTGS2, TP53, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 8.094E-05 | 4.330E-03 | APP, TLR2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 8.094E-05 | 4.330E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 8.094E-05 | 4.330E-03 | GAA, MGAM |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 8.094E-05 | 4.330E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.094E-05 | 4.330E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 8.094E-05 | 4.330E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 8.094E-05 | 4.330E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.094E-05 | 4.330E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.094E-05 | 4.330E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 8.094E-05 | 4.330E-03 | GAA, MGAM |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.094E-05 | 4.330E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 8.094E-05 | 4.330E-03 | ADORA1, ADORA2A |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 8.553E-05 | 4.532E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, EGFR, HSD17B2, NOX4, PTGS2, RAB9A, SLC28A3, TBXAS1 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 8.908E-05 | 4.685E-03 | ABL1, ALOX15, GSK3B, HIF1A, HTT, MAPK1, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.946E-05 | 4.694E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 1.069E-04 | 5.505E-03 | EGFR, MAPT, SYK |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.109E-04 | 5.670E-03 | ABL1, ADORA1, ADORA2A, CA2, CA7, HTT, PARP1 |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 1.213E-04 | 6.126E-03 | AR, DAPK1, HIF1A, HTT, LMNA, MMP9, PTGS2 |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 1.412E-04 | 6.989E-03 | ABL1, ACHE, AKR1B1, APP, CA4, EGFR, HTT, NOX4, NPC1, TNKS2, TYR, USP2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 1.483E-04 | 7.248E-03 | EGFR, ESRRB, HIF1A |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.483E-04 | 7.248E-03 | AHR, ESR1, PPARA |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.484E-04 | 7.248E-03 | ABL1, ADK, AHR, AKR1B1, ALOX5, AR, BLM, CDK6, CSNK2A1, CTDSP1, ESR1, ESR2, ESRRA, ESRRB, FABP5, GSK3B, HIF1A, HTT, LMNA, MAPK1, PARP1, POLB, PPARA, PPARD, RECQL, SMN1, SMN2, STAT6, TNKS, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.613E-04 | 7.687E-03 | TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 1.613E-04 | 7.687E-03 | APP, TLR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.613E-04 | 7.687E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.613E-04 | 7.687E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 1.613E-04 | 7.687E-03 | GAA, MGAM |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.635E-04 | 7.756E-03 | ADORA1, ADORA2A, PPARA, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.723E-04 | 8.122E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.822E-04 | 8.550E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.895E-04 | 8.835E-03 | ABL1, ACHE, ADORA1, CSNK2A1, EGFR, ESRRB, FLT3, MAPT, MMP12, MMP9, PKM, PPARA, SYK, TLR2, TSHR |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 1.991E-04 | 9.184E-03 | ADORA3, APP, AR, CYP1B1, ESR1, ESR2, MAPK1, SYK, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 2.015E-04 | 9.277E-03 | ALOX15, CD38, DAPK1, FABP4, FLT3, GSK3B, HIF1A, MAPK1, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.084E-04 | 9.574E-03 | AKR1B1, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0050730; regulation of peptidyl-tyrosine phosphorylation | 2.118E-04 | 9.710E-03 | ABL1, ADORA1, APP, EGFR, FLT3, SYK, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.160E-04 | 9.880E-03 | HIF1A, LMNA, PPARD, PTGS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.841E-20 | 2.062E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.033E-16 | 6.605E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CFTR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.289E-19 | 2.462E-17 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.164E-10 | 3.022E-08 | CDA; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; HSD17B1; ALOX5; HSD17B2; CD38; AOX1; XDH; CBR1; MGAM; GAA; TYR; CYP2C9; PKM; TBXAS1; CYP1A2; CYP1A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 8.617E-10 | 5.486E-08 | CYP2C9; CBR1; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.257E-08 | 3.429E-07 | GSK3B; FLT3; DAPK1; MMP2; PTGS2; HIF1A; MMP9; EGFR; AR; CDK6; ABL1; MAPK1; TP53; PPARD |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.672E-09 | 2.167E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.313E-09 | 2.167E-07 | CYP2C9; APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.361E-09 | 2.662E-07 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.652E-08 | 3.944E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.562E-08 | 1.180E-06 | DAPK1; MMP2; MAPK1; MMP9; TP53; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.110E-06 | 1.928E-05 | PKM; FLT3; MAPK1; TP53; HIF1A; EGFR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.323E-06 | 1.944E-05 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.844E-06 | 9.937E-05 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; EGFR; TLR2 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.323E-06 | 1.944E-05 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.568E-06 | 2.139E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; CFTR; ABCG2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.849E-06 | 2.207E-05 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.206E-07 | 6.123E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.095E-05 | 1.162E-04 | MMP2; MAPK1; ESR1; MMP9; EGFR; ESR2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.700E-06 | 2.164E-05 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.967E-05 | 1.879E-04 | ABCC1; CDK6; ABL1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; EGFR |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.607E-05 | 6.009E-04 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; TLR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.931E-05 | 1.879E-04 | CYP2C9; CYP1A2; CYP1A1; AOX1; CYP3A4 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.786E-05 | 8.127E-04 | CDK6; MAPK1; STAT6; TP53; MMP9; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.818E-05 | 7.655E-04 | GSK3B; AR; MAPK1; TP53; EGFR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.839E-04 | 1.351E-03 | CDK6; MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.377E-04 | 1.096E-03 | GSK3B; MAPK1; TP53; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.312E-04 | 2.181E-03 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.275E-04 | 2.181E-03 | CDK6; MAPK1; TP53; EGFR |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.839E-04 | 1.351E-03 | FABP4; ADORA1; PTGS2; TSHR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.579E-04 | 2.205E-03 | ABCC1; ADORA3; ADORA1; MAPK1; TP53 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.207E-04 | 2.763E-03 | ADORA2A; ADORA1; MAPK1; PPARA; CFTR; TSHR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.088E-04 | 3.060E-03 | POLB; CDK6; PKM; SYK; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.473E-04 | 2.205E-03 | CDK6; MAPK1; TP53; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.592E-04 | 2.660E-03 | CDK6; MAPK1; TP53; EGFR |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.732E-04 | 2.959E-03 | GSK3B; MAPK1; PPARA; TP53; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.844E-04 | 2.721E-03 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.105E-04 | 2.763E-03 | CDK6; ABL1; MAPK1; TP53 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.722E-03 | 7.308E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; EGFR; TLR2 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 9.891E-04 | 4.723E-03 | GSK3B; ABL1; MAPK1; EGFR |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.630E-03 | 7.078E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.619E-03 | 1.411E-02 | GSK3B; SYK; CSNK2A1; CD38; TP53 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.268E-03 | 5.906E-03 | SYK; CSNK2A1; PARP1; PTGS2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.216E-03 | 1.307E-02 | GSK3B; ABL1; MAPK1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.560E-03 | 2.082E-02 | PARP1; LMNA; MAPK1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.617E-03 | 1.411E-02 | GSK3B; CDK6; ABL1; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 5.843E-03 | 2.090E-02 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 8.463E-03 | 2.787E-02 | CD38; MAPK1; PTGS2; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.001E-03 | 1.246E-02 | FLT3; MAPK1; PPARD |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.317E-02 | 3.812E-02 | FLT3; TP53; MMP9; ELANE |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.020E-03 | 2.090E-02 | GSK3B; SYK; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 6.020E-03 | 2.090E-02 | MAPK1; PTGS2; TLR2 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.102E-02 | 3.340E-02 | MMP2; MAPK1; EGFR |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.810E-03 | 1.455E-02 | GSK3B; MAPK1; TP53 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.419E-02 | 4.046E-02 | GSK3B; MAPK1; TYR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.458E-02 | 4.094E-02 | MAPK1; HIF1A; EGFR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.828E-02 | 4.916E-02 | MAPK1; PTGS2; MMP9 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.251E-03 | 2.132E-02 | CSNK2A1; MAPK1; EGFR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.449E-03 | 2.959E-02 | CDK6; PTGS2; TP53 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.536E-02 | 4.251E-02 | MAPK1; HIF1A; EGFR |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.006E-02 | 3.099E-02 | THPO; FLT3; CD38 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.272E-02 | 3.739E-02 | CA2; CD38; CFTR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.621E-03 | 7.078E-03 | CDA; CYP3A4; XDH |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.596E-04 | 2.660E-03 | MGAM; GAA; AKR1B1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.424E-03 | 6.478E-03 | ABCC1; CFTR; ABCG2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 7.275E-04 | 3.563E-03 | MAOA; AOX1; TYR |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.381E-03 | 2.959E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 8.163E-03 | 2.735E-02 | MAPK1; EGFR |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.739E-02 | 4.744E-02 | PKM; GLO1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.204E-02 | 3.594E-02 | POLB; PARP1 |
| hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 9.381E-03 | 2.959E-02 | AOX1; CD38 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.962E-03 | 2.090E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.500E-04 | 1.769E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; PARP1 |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; ESR1; ESR1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; MMP2; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ELANE; ELANE; MMP12; MMP12; ADORA2A |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK; ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; ADORA2A |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5; SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ADK; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; ADORA2A; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; ABL1; MMP2; ACHE; PTGS2; CD38; GSK3B; ADORA3; HIF1A; MAPK1; MMP9; EGFR; PARP1; TLR2; TP53; ESR1; ESR1; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA; ALOX5; SYK; ELANE; PTGS2; PTGS2; PTGS2; PTGS2; TYR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; EGFR; EGFR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE; ADORA2A; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; PARP1; TLR2; TYR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PKM; CDA; SYK; FLT3; CA9; ABL1; MMP2; HIF1A; MAPK1; MMP9; EGFR; TLR2; TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM; PTGS2; PPARD |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; EGFR; TLR2; ESR1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ESRRA; ALOX5; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; TBXAS1; ESRRA; ALOX5; ALOX5; SYK; SYK; ELANE; MMP12; PTGS2; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; APP |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADORA2A; ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; ELANE; MMP12; PTGS2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ADORA1; TLR2; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; ELANE; ELANE; CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; GSK3B; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; PTGS2; EGFR; TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; CD38; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; EGFR; EGFR; TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE; PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |